Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of Various Formulations of PWT-143 in Healthy Subjects
Sponsor: MEI Pharma, Inc.
This PHASE1 trial investigates Malignancies and is currently completed. MEI Pharma, Inc. leads this study, which shows 6 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 1 earlier version
-
Jan 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MEI Pharma, Inc.
- Quotient Clinical
For direct contact, visit the study record on ClinicalTrials.gov .